Neoadjuvant Therapy in Differentiated Thyroid Cancer

Table 3

Rates of residual tumor after resection in differentiated thyroid cancer.

Author and year	Sample size	Neoadjuvant chemotherapy	R0, R1, R2
Besic et al., 2012 [11]	29 with T3 or T4 follicular or Hurthle cell thyroid cancer.	Vinblastine, vinblastine with doxorubicin, or other regimens.	51.7%, 34.5%, and 13.8%.
Besic et al., 2013 [12]	16 with T3 or T4 papillary thyroid cancer.	Vinblastine, vinblastine with doxorubicin, or other regimens.	12.5%, 62.5%, and 25%.
Hartl et  al., 2014 [14]	46 with extensively invasive DTC.	None.	49%, 51%, and 0%.

Definitions: DTC: differentiated thyroid cancer, R0: resection with no residual tumor, R1: resection with microscopic residual tumor, and R2: resection with macroscopic residual tumor.
is considered inoperable prior to neoadjuvant treatment.